{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,6]],"date-time":"2026-05-06T05:10:30Z","timestamp":1778044230954,"version":"3.51.4"},"reference-count":37,"publisher":"MDPI AG","issue":"5","license":[{"start":{"date-parts":[[2026,4,24]],"date-time":"2026-04-24T00:00:00Z","timestamp":1776988800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"Gilead"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Viruses"],"abstract":"<jats:p>Objectives: The World Health Organization (WHO) goal of eradicating hepatitis C virus (HCV) infection by 2030 has encouraged healthcare providers to implement proactive strategies to improve diagnosis and treatment. The aims of this retrospective cohort study were to assess a program designed to improve the HCV care cascade and facilitate access to treatment, within a national healthcare provider in Israel, Maccabi Healthcare Services (MHS). Methods: Included were adult patients newly diagnosed with HCV infection before and after the implementation of a screening and care optimization program. Patients diagnosed in 2017 served as the reference group (RG), while those diagnosed in 2019 (following the program implementation) comprised the intervention group (IG). Study outcomes included completion of HCV laboratory testing, time to consultation with gastroenterologist\/hepatologist (GE), and initiation of treatment with direct-acting antivirals (DAAs). Results: The study sample included 356 HCV Ab+ patients in the RG (median age = 46 years; 41% females), and 328 in the IG (median age = 48 years; 39% females). Compared to RG, IG demonstrated higher rates of patient visiting GE visit (78.1% vs. 63%) and initiating DAA treatment (66.3% vs. 35.5%). Conclusions: Implementation of a restructured HCV care cascade was associated with a greater proportion of patients receiving expert consultation and higher DAA treatment uptake, important steps towards HCV eradication.<\/jats:p>","DOI":"10.3390\/v18050499","type":"journal-article","created":{"date-parts":[[2026,5,5]],"date-time":"2026-05-05T11:40:12Z","timestamp":1777981212000},"page":"499","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Real-World Utilization of the HCV Care Cascade Before and After Implementation of a Program to Streamline Care and Promote Treatment"],"prefix":"10.3390","volume":"18","author":[{"ORCID":"https:\/\/orcid.org\/0009-0007-9440-5592","authenticated-orcid":false,"given":"Daniella","family":"Rahamim-Cohen","sequence":"first","affiliation":[{"name":"Medical Division, Maccabi Healthcare Services, Tel Aviv 6812509, Israel"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ayelet Aviva","family":"Basson","sequence":"additional","affiliation":[{"name":"Kahn Sagol Maccabi Research and Innovation Center, Maccabi Healthcare Services, Tel Aviv 6812509, Israel"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Clara","family":"Weil","sequence":"additional","affiliation":[{"name":"Kahn Sagol Maccabi Research and Innovation Center, Maccabi Healthcare Services, Tel Aviv 6812509, Israel"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Izana","family":"Kaplan-Lavi","sequence":"additional","affiliation":[{"name":"Medical Division, Maccabi Healthcare Services, Tel Aviv 6812509, Israel"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Odelia","family":"Tassa-Liani","sequence":"additional","affiliation":[{"name":"Gilead Sciences Israel Ltd., Hod Hasharon 4524075, Israel"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yael","family":"Topol","sequence":"additional","affiliation":[{"name":"Medical Division, Maccabi Healthcare Services, Tel Aviv 6812509, Israel"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5189-8995","authenticated-orcid":false,"given":"Gabriel","family":"Chodick","sequence":"additional","affiliation":[{"name":"Kahn Sagol Maccabi Research and Innovation Center, Maccabi Healthcare Services, Tel Aviv 6812509, Israel"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bar","family":"Cohen","sequence":"additional","affiliation":[{"name":"Medical Division, Maccabi Healthcare Services, Tel Aviv 6812509, Israel"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9335-6596","authenticated-orcid":false,"given":"Limor","family":"Adler","sequence":"additional","affiliation":[{"name":"Medical Division, Maccabi Healthcare Services, Tel Aviv 6812509, Israel"},{"name":"Gray Faculty of Medical and Health Sciences, Department of Family Medicine, Tel Aviv University, Tel Aviv 6997801, Israel"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6115-5722","authenticated-orcid":false,"given":"Shirley","family":"Shapiro Ben David","sequence":"additional","affiliation":[{"name":"Medical Division, Maccabi Healthcare Services, Tel Aviv 6812509, Israel"},{"name":"Gray Faculty of Medical and Health Sciences, Department of Family Medicine, Tel Aviv University, Tel Aviv 6997801, Israel"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1968","published-online":{"date-parts":[[2026,4,24]]},"reference":[{"key":"ref_1","unstructured":"(2024, February 29). Available online: https:\/\/www.who.int\/news-room\/fact-sheets\/detail\/hepatitis-c."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"2449","DOI":"10.1002\/hep.29685","article-title":"Toward the elimination of hepatitis C in the United States","volume":"67","author":"Saab","year":"2018","journal-title":"Hepatology"},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"1435","DOI":"10.1053\/j.gastro.2017.12.015","article-title":"Efficacy of NS5A inhibitors against hepatitis C virus genotypes 1\u20137 and escape variants","volume":"154","author":"Gottwein","year":"2018","journal-title":"Gastroenterology"},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"637","DOI":"10.7326\/M16-2575","article-title":"Oral Direct-Acting Agent Therapy for Hepatitis C Virus Infection: A Systematic Review","volume":"166","author":"Nelson","year":"2017","journal-title":"Ann. Intern. Med."},{"key":"ref_5","unstructured":"World Health Organization (2017). Global Hepatitis Report 2017, World Health Organization. Available online: https:\/\/www.who.int\/hepatitis\/publications\/global-hepatitis-report2017\/en\/."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"276","DOI":"10.1111\/liv.15446","article-title":"Securing wider EU commitment to the elimination of hepatitis C virus","volume":"43","author":"Wedemeyer","year":"2023","journal-title":"Liver Int."},{"key":"ref_7","unstructured":"World Health Organization (2018). Guidelines for the Care and Treatment of Persons Diagnosed with Chronic Hepatitis C Virus Infection, World Health Organization."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1016\/S2055-6640(20)30264-8","article-title":"Report from the International Viral Hepatitis Elimination Meeting (IVHEM), 17\u201318 November 2017, Amsterdam, The Netherlands: Gaps and challenges in the WHO 2030 hepatitis C elimination framework","volume":"4","author":"Popping","year":"2018","journal-title":"J. Virus Erad."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"2402","DOI":"10.3748\/wjg.v30.i18.2402","article-title":"Current perspectives of viral hepatitis","volume":"30","author":"Usuda","year":"2024","journal-title":"World J. Gastroenterol."},{"key":"ref_10","doi-asserted-by":"crossref","unstructured":"Taha, G., Ezra, L., and Abu-Freha, N. (2023). Hepatitis C Elimination: Opportunities and Challenges in 2023. Viruses, 15.","DOI":"10.3390\/v15071413"},{"key":"ref_11","doi-asserted-by":"crossref","unstructured":"Montgomery, M.P., Randall, L.M., Morrison, M., Gupta, N., Doshani, M., and Teshale, E. (2023). Hepatitis, C Cascades: Data to Inform Hepatitis C Elimination in the United States. Public Health Rep.","DOI":"10.1177\/00333549231193508"},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"S334","DOI":"10.1093\/infdis\/jiad198","article-title":"Lessons Learned From Global Hepatitis C Elimination Programs","volume":"229","author":"Handanagic","year":"2024","journal-title":"J. Infect. Dis."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1111\/liv.12063","article-title":"Best strategies for global HCV eradication","volume":"33","author":"Hagan","year":"2013","journal-title":"Liver Int."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"1011","DOI":"10.15585\/mmwr.mm7132e1","article-title":"Vital signs: Hepatitis C treatment among insured adults: United States, 2019\u20132020","volume":"71","author":"Thompson","year":"2022","journal-title":"MMWR Morb. Mortal. Wkly. Rep."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"1251","DOI":"10.1001\/jama.2023.3692","article-title":"A National Hepatitis C Elimination Program in the United States: Ahistoric Opportunity","volume":"329","author":"Fleurence","year":"2023","journal-title":"JAMA"},{"key":"ref_16","doi-asserted-by":"crossref","unstructured":"Gomaa, A., Gomaa, M., Allam, N., and Waked, I. (2024). Hepatitis C Elimination in Egypt: Story of Success. Pathogens, 13.","DOI":"10.3390\/pathogens13080681"},{"key":"ref_17","unstructured":"Central Bureau of Statistics (2024, February 29). Publications and Media Releases, Available online: https:\/\/www.cbs.gov.il\/en\/mediarelease\/Pages\/2017\/Projections-of-Israel-Population-until-2065.aspx."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1186\/s13584-017-0172-1","article-title":"Multi-disciplinary patient-centered model for the expedited provision of costly therapies in community settings: The case of new medication for hepatitis C","volume":"6","author":"Avisar","year":"2017","journal-title":"Isr. J. Health Policy Res."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1007\/s12072-018-9902-x","article-title":"Identifying barriers to treatment of HCV in the primary care setting","volume":"13","author":"Johnson","year":"2019","journal-title":"Hepatol. Int."},{"key":"ref_20","doi-asserted-by":"crossref","unstructured":"Zuckerman, A., Douglas, A., Nwosu, S., Choi, L., and Chastain, C. (2018). Increasing success and evolving barriers in the hepatitis C cascade of care during the direct acting antiviral era. PLoS ONE, 13.","DOI":"10.1371\/journal.pone.0199174"},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"922","DOI":"10.1111\/j.1572-0241.2008.01789.x","article-title":"High prevalence of hepatitis C virus infection among immigrants from the former Soviet Union in the New York City metropolitan area: Results of a community-based screening program","volume":"103","author":"Batash","year":"2008","journal-title":"Am. J. Gastroenterol."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"1044","DOI":"10.1002\/jmv.24426","article-title":"Epidemiology of hepatitis C virus infection in a large Israeli health maintenance organization","volume":"88","author":"Weil","year":"2016","journal-title":"J. Med. Virol."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"1189","DOI":"10.1111\/j.1537-2995.2007.01253.x","article-title":"Risk factors for hepatitis C virus infection among blood donors in Israel: A case-control study between native Israelis and immigrants from the former Soviet Union","volume":"47","author":"Kerzman","year":"2007","journal-title":"Transfusion"},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1111\/j.1478-3231.2011.02539.x","article-title":"A systematic review of hepatitis C virus epidemiology in Europe, Canada and Israel","volume":"31","author":"Cornberg","year":"2011","journal-title":"Liver Int."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"293","DOI":"10.7326\/M13-1133","article-title":"Chronic hepatitis C virus infection in the United States, National Health and Nutrition Examination Survey 2003 to 2010","volume":"160","author":"Denniston","year":"2014","journal-title":"Ann. Intern. Med."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"913","DOI":"10.1093\/cid\/ciac255","article-title":"Spontaneous Clearance of Vertically Acquired Hepatitis C Infection: Implications for Testing and Treatment","volume":"76","author":"Ades","year":"2023","journal-title":"Clin. Infect. Dis."},{"key":"ref_27","first-page":"e63881","article-title":"Revolutionizing Healthcare: How Telemedicine Is Improving Patient Outcomes and Expanding Access to Care","volume":"16","author":"Ezeamii","year":"2024","journal-title":"Cureus"},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"504","DOI":"10.1177\/1357633X16670495","article-title":"Telehealth interventions for reducing waiting lists and waiting times for specialist outpatient services: A scoping review","volume":"22","author":"Caffery","year":"2016","journal-title":"J. Telemed. Telecare"},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"873","DOI":"10.1111\/jvh.14010","article-title":"United States Provider Experiences With Telemedicine for Hepatitis C Treatment: A Nationwide Survey","volume":"31","author":"Patel","year":"2024","journal-title":"J Viral Hepat."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1002\/hep4.1627","article-title":"A Population-Based Intervention to Improve Care Cascades of Patients with Hepatitis C Virus Infection","volume":"5","author":"Scott","year":"2020","journal-title":"Hepatol. Commun."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"1270","DOI":"10.1111\/jvh.13399","article-title":"Loss to follow-up in the hepatitis C care cascade: A substantial problem but opportunity for micro-elimination","volume":"27","author":"Drenth","year":"2020","journal-title":"J. Viral Hepat."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"2261","DOI":"10.1111\/liv.14227","article-title":"The population level care cascade for hepatitis C in British Columbia, Canada as of 2018: Impact of direct acting antivirals","volume":"39","author":"Bartlett","year":"2019","journal-title":"Liver Int."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"ofac445","DOI":"10.1093\/ofid\/ofac445","article-title":"The Hepatitis C Care Cascade During the Direct-Acting Antiviral Era in a United States Commercially Insured Population","volume":"9","author":"Ferrante","year":"2022","journal-title":"Open Forum. Infect. Dis."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"1477","DOI":"10.1007\/s11606-020-05701-9","article-title":"HCV Testing and Treatment in a National Sample of US Federally Qualified Health Centers during the Opioid Epidemic","volume":"35","author":"Assoumou","year":"2020","journal-title":"J. Gen. Intern. Med."},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"1069","DOI":"10.4254\/wjh.v13.i9.1069","article-title":"Hepatitis C virus treatment failure: Clinical utility for testing resistance-associated substitutions","volume":"13","author":"Ridruejo","year":"2021","journal-title":"World J. Hepatol."},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"100685","DOI":"10.1016\/j.aohep.2022.100685","article-title":"The impact of COVID-19 on the cascade of care of HCV in the US and China","volume":"27","author":"Yeo","year":"2022","journal-title":"Ann. Hepatol."},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"e2245424","DOI":"10.1001\/jamanetworkopen.2022.45424","article-title":"Characteristics and Treatment Rate of Patients with Hepatitis C Virus Infection in the Direct-Acting Antiviral Era and During the COVID-19 Pandemic in the United States","volume":"5","author":"Nguyen","year":"2022","journal-title":"JAMA Netw. Open"}],"container-title":["Viruses"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/1999-4915\/18\/5\/499\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,6]],"date-time":"2026-05-06T04:11:39Z","timestamp":1778040699000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/1999-4915\/18\/5\/499"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,4,24]]},"references-count":37,"journal-issue":{"issue":"5","published-online":{"date-parts":[[2026,5]]}},"alternative-id":["v18050499"],"URL":"https:\/\/doi.org\/10.3390\/v18050499","relation":{},"ISSN":["1999-4915"],"issn-type":[{"value":"1999-4915","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,4,24]]}}}